NCT05480657View on ClinicalTrials.gov

Safety, Tolerability, and Efficacy of Immunomodulation With AT-1501 in Combination With Transplanted Islet Cells in Adults With Brittle T1D

PHASE1/PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

September 30, 2022

Primary Completion Date

August 31, 2024

Study Completion Date

August 31, 2028

Conditions
Brittle Type 1 Diabetes Mellitus
Interventions
BIOLOGICAL

AT-1501 IV Infusion

Investigational study drug

BIOLOGICAL

Isolated cadaveric islet cells

Infusion of human cadaveric islet cells into the portal vein

Trial Locations (1)

60637

University of Chicago, Chicago

Sponsors
All Listed Sponsors
lead

Eledon Pharmaceuticals

INDUSTRY

NCT05480657 - Safety, Tolerability, and Efficacy of Immunomodulation With AT-1501 in Combination With Transplanted Islet Cells in Adults With Brittle T1D | Biotech Hunter | Biotech Hunter